Amgen Names Thomas Flanagan Senior Vice President and Chief Information Officer
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Sept. 20, 2006--Amgen
(NASDAQ:AMGN), the world's leading biotechnology company, today
announced the appointment of Thomas Flanagan as senior vice president
and chief information officer (CIO). Flanagan replaces Hassan Dayem,
who is retiring.
Flanagan joined Amgen in June 2004 as vice president, Information
Systems, and has been leading Amgen's global enterprise resource
planning program (ERP) since February 2005. Prior to joining Amgen,
Flanagan spent eight years at MCI, where he served in a variety of
executive capacities including CIO and senior vice president of Global
Service Delivery. Before joining MCI in December 1995, he spent 24
years as an officer in the United States Navy.
Dayem joined Amgen in May 2002. Prior to his Amgen appointment, he
served as vice president, Information Services and CIO at Merck & Co.
Before joining Merck, Dayem served in a number of positions at Los
Alamos National Laboratory, including division director, Computing
Information and Communications division.
Amgen discovers, develops and delivers innovative human
therapeutics. A biotechnology pioneer since 1980, Amgen was one of the
first companies to realize the new science's promise by bringing safe
and effective medicines from lab, to manufacturing plant, to patient.
Amgen therapeutics have changed the practice of medicine, helping
millions of people around the world in the fight against cancer,
kidney disease, rheumatoid arthritis, and other serious illnesses.
With a broad and deep pipeline of potential new medicines, Amgen
remains committed to advancing science to dramatically improve
people's lives. To learn more about our pioneering science and our
vital medicines, visit www.amgen.com.
EDITOR'S NOTE: An electronic version of this news release may be
accessed via our Web site at www.amgen.com. Journalists and media
representatives may sign up to receive all news releases
electronically at time of announcement by filling out a short form in
the Media section of the Web site.
CONTACT: Amgen, Thousand Oaks
David Polk, 805-447-4613 (media)
Cory Rivera, 805-447-1060 (investors)